Aloimuniodade contra os antígenos HLA de classe I em pacientes portadores das síndromes mielodisplásticas e de anemia aplástica

• Autor(a) principal: Arruda, Daisy Maria Meireles
• Data de Publicação: 2005
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Repositório Institucional da Universidade Federal do Ceará (UFC)
• dARK ID: ark:/83112/0013000022hhn
• Texto Completo: http://www.repositorio.ufc.br/handle/riufc/1802
• topic: Anemia Aplástica; Sindrome Mielodisplástica; Transfusão de Sangue

Myelodysplastic syndrome (MDS) and aplastic anemia (AA) are two of the hematological disorders which present peripheral cytopenias, with extensive clinical manifestations that vary from slight anemia to severe pancytopenia; the latter requiring continuous transfusional reposition of red cell (RC) and platelet concentrates (PC), which can induce aloimunization in patients. Such patients can develop a post-transfusional refractory state, rendering further transfusions unviable. The objective of the present study was to investigate the incidence of anti-HLA antibodies in politransfused patients, and correlate the aloimmunity levels to the clinical profiles of MDS and AA patients. A total of 110 politransfused patients (70 with MDS, and 40 with AA) have been included in the study, with the MDS patients being subclassified into four clinical diagnostic categories: refractory anemia (RA), ringed-sideroblastic refractory anemia (RSRA), refractory anemia with excess blasts (RAEB) and refractory anemia with excess blasts in transformation (RAEB-t). Blood serum samples from these patients were treated with dithiothreitol for the detection of anti-HLA class I antibodies, using the complement-dependent cytotoxicity test (CDC), in a panel of lymphocytes constituted on the basis of the frequency of HLA antigens in our population (PRA). The results showed that a larger number of AA patients were aloimmunized than MDS patients (45% v 28.6%), with the aloreactivity being higher in AA patients who received higher mean transfusions of PC, than in MDS patients who received higher average number of EC transfusions. The degree of aloimmunization was different in the two disorders, and was generally related to: the number of transfusions received, the application of un-deleukocytised PC and EC, and the type of immunosuppressant drugs used in treatment [Cyclosporin (CsA) and/or antiglobulin (ALG) therapy significantly reduced aloimmunization, but corticoids alone were not sufficient]. The highest degree of aloimmunity (Grade 4) was observed only in MDS females, particularly in those who had multiple births. Persistent IgG was also associated with Grade 4 aloimmunity. These results reveal that significant numbers of MDS and AA patients, if politransfused with un-deleukocytised PC and EC and un-treated with immunosuppressants CsA and/or ALG, can develop anti-HLA antibodies and become refractory to further transfusions. Such aloimmunized patients can also become potentially unsuited to receive bone marrow transplants from HLA-matched donors.